X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare TTK HEALTHCARE with ASTRAZENECA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TTK HEALTHCARE vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TTK HEALTHCARE ASTRAZENECA PHARMA TTK HEALTHCARE/
ASTRAZENECA PHARMA
 
P/E (TTM) x 33.3 117.9 28.2% View Chart
P/BV x 6.1 16.8 36.5% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 TTK HEALTHCARE   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    TTK HEALTHCARE
Mar-14
ASTRAZENECA PHARMA
Mar-14
TTK HEALTHCARE/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs6631,285 51.6%   
Low Rs399634 62.9%   
Sales per share (Unadj.) Rs535.6189.6 282.5%  
Earnings per share (Unadj.) Rs15.9-0.2 -7,832.0%  
Cash flow per share (Unadj.) Rs20.03.8 520.9%  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs137.668.6 200.5%  
Shares outstanding (eoy) m7.7725.00 31.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.05.1 19.6%   
Avg P/E ratio x33.3-4,712.7 -0.7%  
P/CF ratio (eoy) x26.5249.6 10.6%  
Price / Book Value ratio x3.914.0 27.6%  
Dividend payout %25.10-   
Avg Mkt Cap Rs m4,12723,988 17.2%   
No. of employees `0001.71.6 109.6%   
Total wages/salary Rs m6071,605 37.8%   
Avg. sales/employee Rs Th2,436.73,040.2 80.1%   
Avg. wages/employee Rs Th355.21,029.2 34.5%   
Avg. net profit/employee Rs Th72.5-3.3 -2,221.8%   
INCOME DATA
Net Sales Rs m4,1624,740 87.8%  
Other income Rs m6192 66.4%   
Total revenues Rs m4,2234,832 87.4%   
Gross profit Rs m197-130 -151.8%  
Depreciation Rs m32101 31.3%   
Interest Rs m300-   
Profit before tax Rs m197-139 -141.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m735 1,430.3%   
Profit after tax Rs m124-5 -2,434.2%  
Gross profit margin %4.7-2.7 -172.9%  
Effective tax rate %37.0-3.7 -1,010.0%   
Net profit margin %3.0-0.1 -2,772.2%  
BALANCE SHEET DATA
Current assets Rs m1,6292,726 59.7%   
Current liabilities Rs m1,0582,435 43.4%   
Net working cap to sales %13.76.1 223.1%  
Current ratio x1.51.1 137.5%  
Inventory Days Days3074 40.4%  
Debtors Days Days3441 82.4%  
Net fixed assets Rs m5561,035 53.7%   
Share capital Rs m7850 155.4%   
"Free" reserves Rs m878942 93.2%   
Net worth Rs m1,0691,716 62.3%   
Long term debt Rs m1590-   
Total assets Rs m2,3994,156 57.7%  
Interest coverage x7.6NM-  
Debt to equity ratio x0.10-  
Sales to assets ratio x1.71.1 152.1%   
Return on assets %6.4-0.1 -5,233.7%  
Return on equity %11.6-0.3 -3,906.4%  
Return on capital %18.50-  
Exports to sales %0.85.7 13.9%   
Imports to sales %1.46.5 21.7%   
Exports (fob) Rs m33270 12.2%   
Imports (cif) Rs m58306 19.0%   
Fx inflow Rs m33375 8.8%   
Fx outflow Rs m63470 13.4%   
Net fx Rs m-30-96 31.7%   
CASH FLOW
From Operations Rs m127-8 -1,563.0%  
From Investments Rs m-146-146 100.2%  
From Financial Activity Rs m22862 2.5%  
Net Cashflow Rs m3709 0.4%  

Share Holding

Indian Promoters % 65.4 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 3.7 0.3 1,233.3%  
FIIs % 5.2 15.7 33.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.8 9.1 283.5%  
Shareholders   12,723 12,856 99.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TTK HEALTHCARE With:   ORCHID PHARMA LTD  WYETH LTD  ABBOTT INDIA  ALEMBIC LTD  DR. REDDYS LAB  

Compare TTK HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Breaches 36,000 Mark; ONGC Nears 52-Week High(Closing)

The NSE Nifty on Tuesday sailed past the 11,000 mark, while the BSE Sensex breached the 36,000 level for the first time after an IMF report showed India was set to regain.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TTK HEALTHCARE SHARE PRICE


Jan 23, 2018 (Close)

TRACK TTK HEALTHCARE

  • Track your investment in TTK HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TTK HEALTHCARE

TTK HEALTHCARE 8-QTR ANALYSIS

COMPARE TTK HEALTHCARE WITH

MARKET STATS